Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

MLA

Solomon, Benjamin J., et al. “Lorlatinib vs Crizotinib in Treatment-Naïve Patients with Advanced ALK + Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety from the CROWN Study.” Journal of Clinical Oncology, vol. 42, June 2024, p. LBA8503. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8503.

APA

Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., Shaw, A. T., de Marinis, F., Goto, Y., Wu, Y.-L., Kim, D.-W., Martini, J.-F., Messina, R., Paolini, J., Polli, A., Thomaidou, D., Toffalorio, F., & Bauer, T. M. (2024). Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study. Journal of Clinical Oncology, 42, LBA8503. https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8503

Chicago

Solomon, Benjamin J., Geoffrey Liu, Enriqueta Felip, Tony S. K. Mok, Ross Andrew Soo, Julien Mazieres, Alice Tsang Shaw, et al. 2024. “Lorlatinib vs Crizotinib in Treatment-Naïve Patients with Advanced ALK + Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety from the CROWN Study.” Journal of Clinical Oncology 42 (June): LBA8503. doi:10.1200/JCO.2024.42.17_suppl.LBA8503.